



, 가 가  
 Daunomycin(30 mg, 1 /  
 , 4 ), Vincristine(1.8 mg, 1 / , 4 ), L - As -  
 paraginase(8000 U, 3 / , 9 ) dexameth -  
 asone(15 mg, 7 / , 28 ) 2  
 triple intrathecal therapy(Methotrexate 15 mg + Hy -  
 drocortisone 15 mg + Ara - C 30 mg) .

triple intrathecal therapy 4

0.5×0.5 cm

(Fig. 1).

2 :  
 43 1999 5 (AML)



**Fig. 1.** Lateral view of the external nose of a patient with ALL (case 1) after chemotherapy. The cartilaginous part of the dorsum of nose shows dropping (arrow).

7 Ara - C(188 mg, 7 ) , Idarubicin(22.5 mg, 3  
 ) remission induction chemotherapy ,  
 3 가 7  
 5 Ara - C(1800 mg, 5 ) , Etoposide(180  
 mg, 4 ) , Mitoxantrone(18 mg, 3 ) consolidation ch -  
 emotherapy .  
 remission induction chemotherapy 5

가 가 . 가  
 (cephalic portion),  
 (perpendicular plate of ethmoid bone)

(vomer)


(Fig. 2),

가  
 2×2 cm


(Fig. 3).



**Fig. 2.** Lateral view of the external nose of a patient with AML (case 2) after chemotherapy. The cartilaginous part of the dorsum of nose shows dropping (arrow).



**Fig. 3.** Endoscopic view of the septum in a patient with AML (case 2) after chemotherapy. Note the 2×2 cm sized, perforation throughout the cartilaginous and bony septum (arrows). S : septum, IT : inferior turbinate, MT : middle turbinate



**Fig. 4.** Histopathologic finding at the margin of septal perforation in a patient with AML (case 2). The biopsed nasal septum reveals non-osteoclastic erosion of the bony spicule (B) with necrotic inflammatory exudate mainly composed of polymorphonuclear leukocytes. No evidence of cancer cells was found (H & E, ×200).

ction chemotherapy

3 Ara-C(3000 mg, 3 ), Idarubicin(18 mg, 3 ) remission reinduction chemotherapy

6

5

1999 6 Ara-C(200 mg, 2 ) Hydroxyurea(4.0 g, 28 ) cyto reduction chemotherapy

가

1×1 cm

7) Ara-C,<sup>8)9)</sup> L-as-paraginase,<sup>10)</sup> daunomycin<sup>11)</sup>

3

(aseptic necrosis)가 가

3 : 20 1999 6 (AML) 가 1998 2 7 Ara-C(150 mg, 7 ), Daunorubicin(70 mg, 3 ) remission indu-

Ara-C Ara-C 8) 1 intrathecal 30 mg 2 Ara-C 1800 mg 2

5 , 3 Ara - C 3000 mg  
3 . Ara - C가

가 가 가

Ara - C

1 (deep vein  
thrombosis) L - asparaginase<sup>10)</sup>  
daunomycin 11)

#### MOAD

(Methotrexate, Vincristine, L - Asparaginase and Dex -  
amethasone) therapy<sup>12)</sup> systemic steroid<sup>13 - 15)</sup>

1

Ara - C가 septal perforation

Ara - C가

1 4 , 2 3 7  
4~7

2 5

가 2

가 가

가 가

가

(Fig. 4).

가

가

가 가

가

#### REFERENCES

- 1) Ismail HK. Closure of septal perforation. A new technique. *J Laryngol Otol* 1964;78:620-3.
- 2) Fairbanks DN, Fairbanks GR. Nasal septal perforation: prevention and management. *Ann Plast Surg* 1980;5:542-9.
- 3) Younger R, Blokmanis A. Nasal septal perforations. *The Journal of Otolaryngology* 1985;14:125-31.
- 4) Miller FF. Occurrence of nasal septal perforation with use of intranasal dexamethasone aerosol. *Annals of Allergy* 1975;34:107-9.
- 5) Snyder GG 3d, McCarthy RE, Toomey JM, Rothfield NF. Nasal septal perforation in systemic lupus erythematosus. *Arch Otolaryngol* 1974;99:456-7.
- 6) Harris BK, Tello R. Septal perforation with saddle nose deformity in rheumatoid arthritis. *Arthritis Rheum* 1979;22:101-2.
- 7) Loo TL, Freireich EJ. Cancer chemotherapeutic drugs. In: Munson PL, Mueller Ra, Breese GR, editors. *Principles of pharmacology*. New York: Chapman & Hall;1995. p.1475-517.
- 8) Hippe E, Jonsson V, Schroder HD, Jensen TS. Ara-C vasculitis. *Eur J Haematol* 1988;41:96.
- 9) Ahmed I, Chen KR, Nakayama H, Gibson LE. Cytosine arabinoside-induced vasculitis. *Mayo Clin Proc* 1998;73:239-42.
- 10) Castaman G, Rodeghiero F. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia. *Haematologica* 1993;78:57-60.
- 11) Lippman M, Zager R, Henderson ES. High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukemia. *Cancer Chemother Rep* 1972;56:755-60.
- 12) Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Marcus S, Weinberg V, et al. Long-term follow-up of treatment and potential care of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen. *Leukemia* 1993;7:1236-41.
- 13) Abe H, Sako H, Okino K, Nakane Y, Kodama M, Park KI, et al. Clinical study of aseptic necrosis of bone after renal transplantation. *Transplant Proc* 1994;26:1987.
- 14) Weiner ES, Abeles M. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. *J Rheumatol* 1989;16:604-8.
- 15) Grub R, Heni N, Baumeister L. Aseptic necrosis of the femoral head in lymphogranulomatosis and chronic myeloid leukemia treated intermittently with cytostatic agents and steroids. *Radiologie* 1978;18:401-7.